FAIRMOUNT FUNDS MANAGEMENT LLC
Q1 2025 Form 13-F
WEST CONSHOHOCKEN, PENNSYLVANIA
CIK 0001802528
· CRD 284844
· SEC-registered investment adviser
$644.6M Reported Value Total
FAIRMOUNT FUNDS MANAGEMENT LLC reports 3 total accounts under management (AUM). There are 3 discretionary accounts valued at $3,168,724,000, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
12 funds
· $6.1B gross asset value
Hedge Fund: $5.7B · Private Equity Fund: $342.0M
Source: Form ADV filed 2026-08-07
Reported value
$644.6M
Quarter over quarter
-13.8%
Holdings
15
Top-10 concentration
87.3%
Key People
Form ADV owners & control persons
Peter Evan Harwin
MANAGING MEMBER
Tomas Kiselak
MANAGING MEMBER
Emily Florence Curtiss
GENERAL COUNSEL
Filing Navigation
13F Metrics
Loading 13F Metrics
Q1 2025 13F record
Q1 2025 13F filing summary
| Period of report | March 31, 2025 |
|---|---|
| Filed | May 15, 2025 |
| Form | 13F-HR |
| Reported value | $644.6M |
| Positions | 15 |
| Change in reported value | -35.9% |
| New positions | 0 |
| Exited positions | 2 |
| Position turnover | 11.8% |
| Top-10 concentration | 87.3% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
12 | $1.5B |
|
Q1 2026 13F
Filed May 15, 2026
|
12 | $1.4B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
13 | $1.3B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
17 | $1.1B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
17 | $771.9M |
|
Q1 2025 13F
Filed May 15, 2025
|
15 | $644.6M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
17 | $1.0B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
15 | $1.2B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
13 | $885.1M |
|
Q1 2024 13F
Filed May 15, 2024
|
15 | $917.4M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
16 | $946.5M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
20 | $831.2M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
17 | $709.3M |
|
Q1 2023 13F
Filed May 15, 2023
|
16 | $581.5M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
16 | $630.4M |
|
Q3 2022 13F
Filed Nov 9, 2022
|
26 | $568.9M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
27 | $436.9M |
|
Q1 2022 13F
Filed May 16, 2022
|
22 | $422.9M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
20 | $303.3M |
|
Q3 2021 13F
Filed Nov 15, 2021
|
20 | $275.0M |
7 earlier quarters on file — choose one from the quarter menu above.
Top 15 holdings · Q1 2025
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | AXSM AXSOME THERAPEUTICS INC | $95.1M | 14.75% |
| 2 | APGE APOGEE THERAPEUTICS INC | $76.5M | 11.87% |
| 3 | SYRE SPYRE THERAPEUTICS INC | $64.8M | 10.06% |
| 4 | ELVN ENLIVEN THERAPEUTICS INC | $63.0M | 9.78% |
| 5 | NUVL NUVALENT INC | $51.6M | 8.0% |
| 6 | DNTH DIANTHUS THERAPEUTICS INC | $49.0M | 7.6% |
| 7 | VRDN VIRIDIAN THERAPEUTICS INC | $46.4M | 7.21% |
| 8 | SRRK SCHOLAR ROCK HLDG CORP | $44.2M | 6.85% |
| 9 | COGT COGENT BIOSCIENCES INC | $37.3M | 5.79% |
| 10 | ORKA ORUKA THERAPEUTICS INC | $34.6M | 5.37% |
| 11 | KNSA KINIKSA PHARMACEUTICALS INTL | $24.5M | 3.8% |
| 12 | ATXS ASTRIA THERAPEUTICS INC | $19.0M | 2.94% |
| 13 | ZBIO ZENAS BIOPHARMA INC | $15.0M | 2.32% |
| 14 | IKT INHIBIKASE THERAPEUTICS INC | $13.4M | 2.08% |
| 15 | BCAX BICARA THERAPEUTICS INC | $10.2M | 1.59% |
Values as reported on the Q1 2025 Form 13F. Every position is in the holdings table below.